Acute myelogenous leukemia is a complex and heterogeneous disease characterized by an arrest of normal hematopoetic maturation produced by a clone of karyotypically distinct neoplastic cells. The characterization of these neoplastic cells by chromosome analysis strongly predicts for response to induction therapy, risk of relapse, and overall survival. [1] [2] [3] [4] The treatment of one cytogenetic subset, acute promyelocytic leukemia, with disease-specific therapy has led to markedly improved outcome. 5 There are, however, also patients with other cytogenetic subsets of AML such as involving deletions of chromosomes 5 or 7, abnormalities involving chromosome 3, or complex cytogenetics that have a low likelihood of response to conventional chemotherapy, a high risk of relapse and a low probability of prolonged survival. For such patients, no specific treatment has yet been identified. 6 On the basis of the heterogeneous biology of AML, the World Health Organization has classified the disease into specific cytogenetic or molecular subsets. 7 Patients with AML involving translocation of chromosomes 8 and 21, abnormalities of chromosome 16, and translocation of chromosomes 15 and 17 are typically grouped into what is termed favorable-risk AML. Our discussion will focus on the clinical definitions, as well as cytogenetic and biological features of favorable-risk AML. We will also look at prospective studies that have confirmed the distinct clinical features of favorable-risk AML and discuss post-remission therapy for this unique, cytogenetically defined subgroup.
In the early 1980s, acute myelomonocytic leukemia with abnormal eosinophils was identified by distinct abnormal bone marrow morphology, cytochemical staining, and cellular ultrastructure. 8, 9 This subgroup of leukemia also had a distinct abnormality involving chromosome 16. In an early study of 18 patients who were retrospectively identified among 300 patients with newly diagnosed AML, Le Beau and colleagues recognized that this group had a particularly good response to cytarabinebased induction chemotherapy. Furthermore, 10 of 17 evaluable patients remained in first complete remission at the time of the report, thus constituting a group with better than 50% likelihood of leukemia-free survival. 8 In a larger study looking at results only in patients with inv(16) or t(16;16), 31 of 33 such patients had the typical morphologic features of acute myelomonocytic leukemia with abnormal eosinophils. In all, 25 patients achieved complete remission with conventional induction therapy, and nine patients remained in remission more than 2 years after diagnosis. 9 The predictive value of favorable cytogenetics led to a large retrospective study of patients enrolled on acute leukemia trials from 1970 to 1982. 10 In this study, patients with AML characterized by abnormalities involving chromosome 16 were identified as patients in whom complete remission was likely after induction chemotherapy, and in which there was suggestion of improved clinical outcome. Another subgroup that responded similarly to both induction and consolidation treatment consisted of patients with AML with t(8;21). This was confirmed in 2002 by Byrd et al. from the Cancer and Leukemia Group B, who presented a prospective analysis of over 1000 adults with newly diagnosed AML, and identified abnormalities of chromosome 16 and t(8;21) as conferring a significantly better prognosis than normal karyotype. Specifically those with abnormalities of chromosome 16 had an 85% complete remission rate to induction chemotherapy, and those with t(8;21) had 91% complete remission rate. Those with a deletion of the long arm of chromosome 9 also had a high response rate; 94% achieved complete remission. These authors found that a secondary abnormality had an influence on response to induction chemotherapy in the group with t(8;21), leading to a lower rate of complete remission; this lower rate of complete remission did not achieve statistical significance.
In the group of patients with t(15;17), induction chemotherapy initially was reported to produce a variable response based, in large measure, on treatment-related morbidity and mortality. With the introduction of retinoids and better supportive care in the initial period after diagnosis, patients with this cytogenetic abnormality have been identified as likely to enjoy long-term leukemia-free survival. 5 By 1990, recurring chromosome abnormalities in leukemia identified distinct cytogenetic subgroups with powerful implications for response to induction treatment and leukemia-free survival. 12 Several large clinical trials supported the importance of diagnostic cytogenetics on the outcome of both induction and post-remission therapies. 13 Again, the Cancer and Leukemia Group B presented a randomized trial of single-agent doseintensified cytarabine consolidation chemotherapy and confirmed a significant advantage in both leukemia-free and overall survival for patients identified as having disease involving corebinding factors, that is, patients with abnormalities in chromosome 16 and the t(8;21) translocation. Furthermore, the group identified multiple cycles of intensification as most favorably affecting those with leukemia characterized by favorable cytogenetics. 1, 11 In a large study from the United Kingdom involving 1966 children and adults with newly diagnosed de novo 11 or secondary AML, the MRC identified the cytogenetic risk group as the most important predictor of relapse. Both cytogenetics and age were important predictors of post-transplant survival. 2 These data have confirmed a clinical observation; that is, that karyotype has a major prognostic significance for response to induction chemotherapy and implications for long-term survival. 12 The important question that followed rested on whether post-remission treatment differed with respect to antileukemia efficacy, toxicity, and feasibility depending on pre-treatment prognostic factors. Several trials suggested that the answer was yes. In one study from the Cancer and Leukemia Group B, cytarabine intensification led to different results among different cytogenetic groups, with the greatest potential efficacy accruing to those with most favorable pretreatment features. 1, 11 These results have been confirmed irrespective of the intensification regimen.
14 In a study of 70 patients in Vancouver, St Louis, and the Cleveland Clinic, abnormal karyotype was highly predictive of relapse after a single cycle of high-dose cytarabine and daunorubicin consolidation. 15 Those most likely to achieve a favorable response were those in a favorable cytogenetic risk group. In a much larger trial of older adults with AML in the United Kingdom, two inductions followed either by no further therapy or by a consolidation chemotherapy regimen consisting of three courses of cyclophosphamide, vincristine, cytarabine, and prednisolone followed by repeat induction and consolidation showed that the group with favorable karyotype at diagnosis had a significantly increased likelihood of long-term leukemiafree survival, 38%, compared to less than 5% for those with the most adverse cytogenetic features. 15 Finally, in a trial of four cycles of cytarabine-based consolidation chemotherapy, the group with the most favorable karyotype was the group most likely to derive benefit from this intensification scheme. When analyzed on the basis of cytarabine dose in consolidation chemotherapy, again the patients with the most favorable cytogenetics were most likely to achieve a favorable response to dose intensification.
14 Those with adverse cytogenetics at diagnosis were not likely to achieve benefit with doseintensified consolidation chemotherapy. 15, 16 The meaning of a favorable response generally indicates an overall survival rate of about 50-60% for patients who achieve remission after therapy for AML with abnormalities involving chromosome 16, t(8;21), and perhaps even for the group that has deletion involving the long arm of chromosome 9.
11
An improved response to dose-intensified consolidation chemotherapy can also be seen with other forms of postremission treatment. Karyotype has a strong influence after either allogeneic or autologous transplantation in first complete remission. In a study from France, patients with AML characterized by favorable cytogenetic abnormalities achieved a 68% long-term survival when treated with allogeneic transplant in first complete remission, as compared to a 30% survival achieved for the group with adverse cytogenetics. 17 Autologous transplantation likewise benefited those with AML characterized by either standard or favorable prognostic features, and was less effective for those with poor-prognosis cytogenetics (54 vs 33%, respectively). Thus, a picture emerges of a distinct subset of AML characterized by favorable cytogenetics for which our current therapies for induction are likely to achieve complete remission, and for which our current consolidation therapies, be it high-dose cytarabine, allogeneic or autologous transplant, are likely to achieve the best results. [16] [17] [18] The 3-year leukemia-free survival after either allogeneic or autologous transplant for those with abnormalities involving chromosome 16 were 74 and 61%, respectively. The results in those with leukemia characterized by t(8;21) were 65 and 58%, respectively. 17 Thus, the best results of post-remission transplant were achieved in patients with disease characterized by the most favorable cytogenetic abnormalities. Finally, when evaluating the outcome of allogeneic bone marrow transplant carried out in first complete remission, karyotype had a significant impact on leukemia-free survival, with the alternative groups of patients, those with intermediate or adverse cytogenetic features having a significantly poorer likelihood of prolonged survival.
The molecular mechanisms that underlie leukemia characterized by favorable cytogenetics typically involve DNA-binding proteins. Abnormalities involving chromosome 16 seem to involve the same genes. 19 CBFb codes for a protein which is a subunit of a DNA-binding protein complex, core-binding factor. MYH11 codes for a smooth muscle form of a myosin heavy chain gene. The DNA-binding target for core-binding factor is in the promoter/enhancer region of many genes expressed in hematopoietic cells. Thus, an abnormality involving CBFb may play a significant role in the molecular pathogenesis of acute leukemia involving these chromosome abnormalities. Disease involving t(8;21) produces a distinct transgene involving two known oncogenes, AML1 and ETO. AML1-ETO may function as a repressor of transcription and may lead to the downregulation of CCAAT/enhancer-binding proteina, a transcription factor involved in the regulation of myelopoesis. The best characterized mechanism of oncogenesis involves acute leukemia characterized by t(15;17), in which there is a fusion protein derived from the transgene PML/RARa which inhibits DNA binding of C/EBPa. AML characterized by favorable cytogenetics consists of at least two distinct molecular subgroups, those characterized by the PML/RARa, and those characterized by what has been called core-binding factor abnormalities. 20 Patients with primary leukemia characterized by these molecular and cytogenetic markers represent a group with favorable response to our current induction chemotherapy. Furthermore, these cytogenetic abnormalities are important prognostic indicators for cure following intensive post-remission chemotherapy, autologous or allogeneic transplantation. In fact, regardless of the type of post-remission therapy, favorable type AML is still favorable, but characterized by a risk of relapse in the range of 30-50%. 18, 21, 22 The identification of distinct molecular mechanisms that underlie prognostic groups may not constitute a surrogate marker of pretreatment characteristics such as age, antecedent hematologic disorder, or leukocyte count, 23, 24 but rather identify a distinct pathogenesis to be used in developing strategies for future disease-specific therapy. 25 
